Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate

T. Di Paolantonio, G. Mariani, A. Chirardini, A. Gringeri, P. Mannuccio Mannucci, L. Mastrullo, R. De Biasi, G. Giustarini, M. Morfini, M. Schiavoni, N. Ciavarella, G. Zehender, A. R. Zanetti

Research output: Contribution to journalArticle

Abstract

A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.

Original languageEnglish
Pages (from-to)71-74
Number of pages4
JournalJournal of Medical Virology
Volume36
Issue number2
Publication statusPublished - 1992

Fingerprint

Factor VIII
Detergents
HIV-1
Viruses
Antibodies
HIV-2
HIV
Polymerase Chain Reaction
Western Blotting
Antigens

Keywords

  • Chemical inactivation
  • HIV safety
  • HIV-1 PCR
  • Viral inactivation

ASJC Scopus subject areas

  • Virology

Cite this

Di Paolantonio, T., Mariani, G., Chirardini, A., Gringeri, A., Mannuccio Mannucci, P., Mastrullo, L., ... Zanetti, A. R. (1992). Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate. Journal of Medical Virology, 36(2), 71-74.

Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate. / Di Paolantonio, T.; Mariani, G.; Chirardini, A.; Gringeri, A.; Mannuccio Mannucci, P.; Mastrullo, L.; De Biasi, R.; Giustarini, G.; Morfini, M.; Schiavoni, M.; Ciavarella, N.; Zehender, G.; Zanetti, A. R.

In: Journal of Medical Virology, Vol. 36, No. 2, 1992, p. 71-74.

Research output: Contribution to journalArticle

Di Paolantonio, T, Mariani, G, Chirardini, A, Gringeri, A, Mannuccio Mannucci, P, Mastrullo, L, De Biasi, R, Giustarini, G, Morfini, M, Schiavoni, M, Ciavarella, N, Zehender, G & Zanetti, AR 1992, 'Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate', Journal of Medical Virology, vol. 36, no. 2, pp. 71-74.
Di Paolantonio, T. ; Mariani, G. ; Chirardini, A. ; Gringeri, A. ; Mannuccio Mannucci, P. ; Mastrullo, L. ; De Biasi, R. ; Giustarini, G. ; Morfini, M. ; Schiavoni, M. ; Ciavarella, N. ; Zehender, G. ; Zanetti, A. R. / Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate. In: Journal of Medical Virology. 1992 ; Vol. 36, No. 2. pp. 71-74.
@article{caa57a58143d4b5fbabdb0a7cae82838,
title = "Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate",
abstract = "A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.",
keywords = "Chemical inactivation, HIV safety, HIV-1 PCR, Viral inactivation",
author = "{Di Paolantonio}, T. and G. Mariani and A. Chirardini and A. Gringeri and {Mannuccio Mannucci}, P. and L. Mastrullo and {De Biasi}, R. and G. Giustarini and M. Morfini and M. Schiavoni and N. Ciavarella and G. Zehender and Zanetti, {A. R.}",
year = "1992",
language = "English",
volume = "36",
pages = "71--74",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate

AU - Di Paolantonio, T.

AU - Mariani, G.

AU - Chirardini, A.

AU - Gringeri, A.

AU - Mannuccio Mannucci, P.

AU - Mastrullo, L.

AU - De Biasi, R.

AU - Giustarini, G.

AU - Morfini, M.

AU - Schiavoni, M.

AU - Ciavarella, N.

AU - Zehender, G.

AU - Zanetti, A. R.

PY - 1992

Y1 - 1992

N2 - A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.

AB - A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.

KW - Chemical inactivation

KW - HIV safety

KW - HIV-1 PCR

KW - Viral inactivation

UR - http://www.scopus.com/inward/record.url?scp=0026585223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026585223&partnerID=8YFLogxK

M3 - Article

C2 - 1583469

AN - SCOPUS:0026585223

VL - 36

SP - 71

EP - 74

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 2

ER -